Group 1 - The company, Zhejiang Haizheng Pharmaceutical Co., Ltd., announced that its wholly-owned subsidiary, Haizheng Nantong Co., Ltd., received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration [1] - The GMP inspection was conducted from October 31 to November 2, 2025, and concluded that the production lines and products met the required standards [1] - The inspection involved the production of Minocycline Hydrochloride, which is the first GMP compliance check for this product prior to its market launch [2] Group 2 - The production lines for Minocycline Hydrochloride have seen a total fixed asset investment of approximately 99.16 million yuan, with about 86.30 million yuan already completed [1] - Minocycline Hydrochloride is indicated for infections caused by various sensitive pathogens and was originally developed by Wyeth Pharmaceuticals [2] - In 2024, the global sales volume of Minocycline Hydrochloride was approximately 35,658.87 kg, with domestic sales accounting for about 7,914.50 kg [2]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration for its subsidiary, Haizheng Pharmaceutical Nantong Co., Ltd, indicating successful compliance with GMP standards for its newly established production line of Minocycline Hydrochloride [1] Group 1: GMP Compliance and Production - The GMP compliance inspection for Minocycline Hydrochloride is the first for this drug prior to its market launch, and it is the first successful GMP compliance check for the newly built production line [1] - The total fixed asset investment in the relevant workshop has reached approximately 99.16 million yuan, with about 86.3 million yuan already completed (unaudited) [1] - The successful GMP compliance indicates that the production line and drug meet GMP requirements, which will help the company diversify its product offerings and maintain stable production capacity to meet market demand [1] Group 2: Market Context and Competitors - Minocycline Hydrochloride is used to treat infections caused by various sensitive pathogens, with the original manufacturer being Wyeth Pharmaceuticals in the United States [1] - Major domestic manufacturers of Minocycline Hydrochloride include Haizheng Nantong Co., Ltd and Zhejiang Changhai Pharmaceutical Co., Ltd [1] - The approval notice for the market launch of Minocycline Hydrochloride was obtained in August 2025, indicating a future market entry [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received a GMP compliance inspection notice from the Jiangsu Provincial Drug Administration for its subsidiary, Haizheng Pharmaceutical Nantong Co., Ltd, indicating successful compliance with GMP standards for its newly established production line of Minocycline hydrochloride [1] Group 1: GMP Compliance and Production - The GMP compliance inspection for Minocycline hydrochloride is the first inspection prior to its market launch, and it is the first successful GMP compliance check for the newly built production line [1] - The total fixed asset investment in the relevant workshop has reached approximately 99.16 million yuan, with about 86.3 million yuan already completed (unaudited) [1] - The successful GMP compliance indicates that the production line and the drug meet GMP requirements, which will help the company diversify its product range and maintain stable production capacity to meet market demand [1] Group 2: Product Information - Minocycline hydrochloride is used to treat infections caused by various sensitive pathogens, including Staphylococcus, Streptococcus, and Escherichia coli, among others [1] - The original manufacturer of Minocycline hydrochloride is Wyeth Pharmaceuticals, a U.S. company [1] - Major domestic manufacturers of Minocycline hydrochloride include Haizheng Nantong Co., Ltd and Zhejiang Changhai Pharmaceutical Co., Ltd [1]